Skip to main content
SpringerLink
Log in

The Role of Radiation Therapy

  • Chapter
  • First Online:
Diffuse Gastric Cancer

  • 350 Accesses

Abstract

The Intergroup 0116 (INT 0116) has established chemoradiation as the standard treatment for resected gastric cancer in Western countries. More recently, there has been a debate on the role of radiation in the treatment of diffuse-type adenocarcinoma of the stomach. Here we discuss the evidence and controversies that surround this issue. At this point of current knowledge, we recommend adjuvant chemoradiation for the treatment of resected diffuse-type adenocarcinoma of the stomach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

5-FU + LV:

5-fluorouracil plus leucovorin

CMT:

Chemotherapy

CRT:

Chemoradiation

CT:

Computerized tomography

DFS:

Disease-free survival

Gy:

Gray

HR:

Hazard ratio

OR:

Odds ratio

OS:

Overall survival

RFS:

Relapse-free survival

RT:

Radiation therapy

XP:

Capecitabine and cisplatin

XRT:

Capecitabine with radiation therapy

References

  1. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  2. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

    Article  CAS  PubMed  Google Scholar 

  3. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75(2):110–2.

    Article  CAS  PubMed  Google Scholar 

  5. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group Br J Cancer. 1999;79(9–10):1522–30.

    PubMed  CAS  Google Scholar 

  6. Viste A, Svanes K, Janssen CW Jr, Maartmann-Moe H, Søreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. Eur J Surg. 1994;160(9):497–502.

    PubMed  CAS  Google Scholar 

  7. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.

    Article  PubMed  Google Scholar 

  9. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.

    Article  CAS  PubMed  Google Scholar 

  10. Park SH, Sohn TS, Lee J, do DH L, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.

    Article  CAS  PubMed  Google Scholar 

  11. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  12. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

    Article  PubMed  Google Scholar 

  13. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.

    Article  PubMed  Google Scholar 

  14. Stessin AM, Sison C, Schwartz A, Ng J, Chao CK, Li B. Does adjuvant radiotherapy benefit with diffuse-type gastric cancer? Results from the surveillance, epidemiology, and end results database. Cancer. 2014;120(22):3562–8.

    Article  PubMed  Google Scholar 

  15. Dai Q, Jian L, Lin RJ, Wei KK, Gan LL, Deng CH, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J Surg Oncol. 2015;111(3):277–84.

    Article  PubMed  Google Scholar 

  16. Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Italian research Group for Gastric Cancer. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26(9):1160–5.

    Google Scholar 

  17. Vasconcelos K, Chen ATC, Hong CBC, Nakazato D, Stelko G, Hoff PMG, et al. Liver irradiation increases relapse-free survival in adjuvant gastric cancer treatment. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl 2257):S301.

    Article  Google Scholar 

  18. Park SH, Lee SJ, Kim ST, Lee J, Park JO, Park YS, et al. Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2). J Clin Oncol. 2015;33(Suppl 3):TPS228.

    Article  Google Scholar 

  19. Verheij M, Jansen EPM, Cats A, van Grieken NCT, Aaronson NK, Boot H, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol. 2016;34(Suppl 15):4000.

    Article  Google Scholar 

  20. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83497.

  21. Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12(2):187–95.

    Article  PubMed  Google Scholar 

  22. Ashman JB, Callister MD, Jaroszewski DE, Ross HJ, Ezzell GA, Gunderson LL. Trimodality therapy for distal esophageal/esophagogastric junction adenocarcinoma using three-dimensional conformal and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(3 Suppl 2222):S303.

    Article  Google Scholar 

  23. Chopra S, Agarwal A, Engineer R, Dora T, Thomas B, Sonawone S, et al. Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: a matched pair analysis. J Cancer Res Ther. 2015;11(3):623–9.

    Article  CAS  PubMed  Google Scholar 

  24. Trip AK, Nijkamp J, van Tinteren H, Cats A, Boot H, Jansen EP, et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiother Oncol. 2014;112(2):289–94.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil

    Andre Tsin Chih Chen

  2. Faculdade de Medicina da Universidade de São Paulo/Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil

    Carlos Bo Chur Hong

Authors
  1. Andre Tsin Chih Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Bo Chur Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andre Tsin Chih Chen .

Editor information

Editors and Affiliations

  1. Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil

    Tiago Biachi de Castria

  2. CLION, Salvador, Bahia, Brazil

    Rodrigo Santa Cruz Guindalini

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, A.T.C., Hong, C.B.C. (2018). The Role of Radiation Therapy. In: de Castria, T., Guindalini, R. (eds) Diffuse Gastric Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-95234-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95234-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95233-8

  • Online ISBN: 978-3-319-95234-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation